Do Defects in the Innate Immune System Contribute to Non-Cystic Fibrosis Bronchiectasis in Maori and Pacific Island Children?

Not Applicable

• Conditions: on-Cystic Fibrosis Bronchiectasis in Maori and Pacific Island Children; Innate Immune Defects in Maori and Pacific Island Children; Non-Cystic Fibrosis Bronchiectasis in Maori and Pacific Island Children; Respiratory - Other respiratory disorders / diseases; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12613001164785
• Lead Sponsor: Starship Clinical Immunology and Allergy Department

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Bronchiectasis group: <15 years old at time of enrolment, Maori or Pacifica, confirmed bronchiectasis on HRCT scan, clinical diagnosis by respiratory physician, consent to study.
Healthy control group: <15 years old at time of enrolment, Maori or Pacifica, consent to study.

Exclusion Criteria

Bronchiectasis group: Cystic fibrosis not excluded as diagnosis, known primary immunodeficiency, primary ciliary dyskinesia, non-consent to study.
Healthy control group: Infectious comorbidities, history of recurrent infections or Rheumatic Fever, non-consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To detect defects in the innate immune system in Maori and Pacifica children with bronchiectasis by measurement of CD62 Ligand shedding using flow cytometry.[Once only within one year of study commencement]

Secondary Outcome Measures

Name	Time	Method
tility of CD62 Ligand shedding assay using flow cytometry as a screen for innate immune defects.[Once only within one year of study commencement]